TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05954741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor rehabilitation alone
Description: Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor rehabilitation and Cognitive rehabilitation (paper-based)
Description: Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor rehabilitation and cognitive rehabilitation (digital-based)
Description: Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
Study: NCT06050122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib Topical Gel
Description: Patidegib Gel 2% is a smooth, clear, colorless-to-yellow, viscous, hydro-alcoholic gel for topical administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patidegib Topical Gel with no active patidegib
Description: Vehicle Gel consists of the excipients of Patidegib Gel with no active patidegib. It is a smooth viscous gel for topical administration.
Study: NCT06371300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Red LLLT
Description: Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red LLLT
Description: Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue LLLT
Description: Mask with LEDs emitting at wavelengths of 428nm to facial and eyelid regions with their eyes closed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Red LLLT
Description: Mask with LEDs emitting at wavelengths of 633nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Blue LLLT
Description: Mask with LEDs emitting at wavelengths of 428nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
Study: NCT06605703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion-Naltrexone-Metformin
Description: Bupropion-Naltrexone-Metformin
Study: NCT06602193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122 225 mg
Description: Administered as specified in the treatment arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BIIB122-Matching Placebo
Description: Administered as specified in the treatment arm
Study: NCT06609590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block
Description: Ultrasound guided anterior glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block
Study: NCT06292481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Brunnstorm Movement therapy and low level laser therapy
Description: this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
Study: NCT05679024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 milligram Oral Tablet
Description: Oral Tablet
Study: NCT05365308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical supports
Description: Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
Study: NCT04853563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
Study: NCT05822089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
Study: NCT05667519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional guidance of lead implantation by transesophageal echocardiography
Description: Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position
Study: NCT06609590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Description: Ultrasound guided interscalene brachial plexus block
Study: NCT06586606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1708
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1708
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral administration
Study: NCT05822089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
Study: NCT06595238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: IMP injected subcutaneously, once a week. Unit dose strength as per CSP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: IMP injected subcutaneously, once a week. Unit dose strength as per CSP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Study: NCT05822089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed
Study: NCT05915091

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch

Intervention type: OTHER
Group type: OTHER
Intervention: Cross Friction Massage
Description: Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
Study: NCT05005026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 1
Description: Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 2
Description: Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study: NCT04523168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Neovasc Reducer™ System
Description: A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
Study: NCT06558617

Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F Questionnaire
Description: The SARC-F scale consists of five components: strength, walking assistance, rising from a chair, stair climbing, and falls. These elements were selected to reflect changes in health status related to the effects of sarcopenia. Scores on the SARC-F scale range from 0 to 10, composed of five domains, assesses strength, walking assistance, raising from a chair, stair climbing and falls. Each domain score ranges from 0-2. A SARC-F score of ≥4 was considered abnormal. The Thai-version SARC-F questionnaire has been validated in Thai older adults.

Intervention type: DIAGNOSTIC_TEST
Intervention: Calf Circumference Measurement
Description: Calf circumference was measured using a nonelastic tape measure while the participant was standing with relaxed legs. The tape was placed snugly and flat around the widest part of the calf, parallel to the floor. According to the AWGS 2019 criteria, calf circumferences were considered abnormal if they were less than 34 cm for males and less than 33 cm for females.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-CalF Questionnaire
Description: This questionnaire integrates the SARC-F and calf circumference as a trigger for case finding. If the calf circumference is below the cut-off value, 10 points are added to the SARC-F score for evaluation. The SARC-CalF score ranges from 0 to 20, with a score of ≥11 considered abnormal for sarcopenia screening.
Study: NCT06270225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg
Description: Subjects will receive 0.5mg/d Colchicine for 12 weeks.
Study: NCT04853329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO107
Description: CD20-CD47 Bispecific Fusion Protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO107
Description: CD20-CD47 Bispecific Fusion Protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO107
Description: CD20-CD47 Bispecific Fusion Protein
Study: NCT06685250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study: NCT06683703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone combined with Bevacizumab
Description: The initial dose was Utidelone 30mg/m2/d,D1-D5,Q3W+ Bevacizumab 15mg/kg/Q3w. If dose adjustment was required due to DLT events, Utidelone was reduced by up to one dose (to 25mg/m2/d), while the dose of Bevacizumab remained unchanged (15mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone injection, 30mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle
Study: NCT06411444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grape Design Nasal Stent
Description: Grape Design Nasal Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grape Design Nasal Stent
Description: Grape Design Nasal Stent
Study: NCT05859815

Intervention type: BEHAVIORAL
Intervention: Physical Therapy
Description: As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.

Intervention type: BEHAVIORAL
Intervention: Physical Therapy
Description: As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
Study: NCT06134414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
Study: NCT06229678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG Oral Tablet
Description: Empagliflozin 25MG will be administered orally once per day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered orally once per day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox 250 Mg Oral Capsule
Description: subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acipimox 250 Mg Oral Capsule
Description: subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies
Study: NCT05561621

Intervention type: OTHER
Intervention: Voice analysis
Description: Voice analysis

Intervention type: OTHER
Intervention: Voice analysis
Description: Voice analysis
Study: NCT05619692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Softgel lipid capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-718-matching Placebo
Description: Softgel lipid capsules.
Study: NCT06595238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo matching IMP dose injected subcutaneously, once a week.
Study: NCT06165354

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo X-secret
Description: In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC.
Study: NCT06120803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
Study: NCT05024682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional pulsed radiofrequency
Description: After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse dosed pulsed radiofrequency
Description: After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).
Study: NCT05262491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study: NCT06177743

Intervention type: DEVICE
Intervention: Coroflex ISAR NEO stent
Description: Percutaneous coronary intervention with Coroflex ISAR NEO stent
Study: NCT04830462

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin 300 Mg Oral Capsule
Description: Rifampicin 600 mg orally once daily for 4 months

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin 300 Mg Oral Capsule
Description: Rifampicin 600 mg orally once daily for 4 months

Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid 300 Mg ORAL TABLET
Description: Isoniazid 300 mg daily for 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid 300 Mg ORAL TABLET
Description: Isoniazid 300 mg daily for 6 months
Study: NCT05266313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oncosexology program
Description: Thematic workshops throughout the year
Study: NCT04994847

Intervention type: DRUG
Intervention: Amyloid and Tau PET
Description: NAV4694 and MK6240 PET scans completed every two years
Study: NCT06338826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
Description: The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
Description: dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
Study: NCT04489719

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study: NCT06371807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: (KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: (KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting